← Leaderboards
Lukas Edward Dow
Weill Medical Coll Of Cornell Univ
$10,323,278
Attributed
$11,586,269
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,586,269 · 7
By mechanism
R01$11,002,097 · 6
K22$584,172 · 1
Top collaborators
- Alejandro Gutierrez3 shared
- Rohit Chandwani1 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Stefan Ross Torborg$231,114
- Kenneth L Pitter$2,110,014
- Emma M Schatoff$179,453
- Ashley Marie Laughney$5,111,057
- Rohit Chandwani$1,965,080
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseMutationTumorOncogenicTargeted TreatmentColorectal CancerTp53 GeneBiological ModelsCellsMalignant NeoplasmsIn VivoTumor ProgressionEffective TherapyComplexResistanceBiologyPathway InteractionsSignal TransductionTherapeutic InterventionIntestinesClustered Regularly Interspaced Short Palindromic RepeatsMutantAnimal ModelBase
Grant awards (22)
Tumor selective inhibition of the WNT pathway$1,159,628
R01 · FY2025 · CA · contact PI
Defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants$636,046
R01 · FY2025 · CA
Mechanisms of genetic and non-genetic resistance to KRAS inhibition$607,849
R01 · FY2025 · CA · contact PI
Tumor selective inhibition of the WNT pathway$550,824
R01 · FY2024 · CA · contact PI
Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer$619,814
R01 · FY2023 · CA
In Vivo Base Editing for Precision Oncology Models$590,350
R01 · FY2023 · CA · contact PI
Tumor selective inhibition of the WNT pathway$568,218
R01 · FY2023 · CA · contact PI
Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer$618,702
R01 · FY2022 · CA
In Vivo Base Editing for Precision Oncology Models$597,206
R01 · FY2022 · CA · contact PI
Tumor selective inhibition of the WNT pathway$597,189
R01 · FY2022 · CA · contact PI
Progression, response, and resistance of RSPO fusion colorectal cancer$376,511
R01 · FY2022 · CA · contact PI
Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer$651,421
R01 · FY2021 · CA
In Vivo Base Editing for Precision Oncology Models$616,320
R01 · FY2021 · CA · contact PI
Progression, response, and resistance of RSPO fusion colorectal cancer$384,298
R01 · FY2021 · CA · contact PI
In Vivo Base Editing for Precision Oncology Models$623,053
R01 · FY2020 · CA · contact PI
Progression, response, and resistance of RSPO fusion colorectal cancer$384,399
R01 · FY2020 · CA · contact PI
In Vivo Base Editing for Precision Oncology Models$646,960
R01 · FY2019 · CA · contact PI
Progression, response, and resistance of RSPO fusion colorectal cancer$377,180
R01 · FY2019 · CA · contact PI
Progression, response, and resistance of RSPO fusion colorectal cancer$396,129
R01 · FY2018 · CA · contact PI
Defining the genetic requirements for maintenance of colorectal cancer$194,724
K22 · FY2016 · CA · contact PI
Defining the genetic requirements for maintenance of colorectal cancer$194,724
K22 · FY2015 · CA · contact PI
Defining the genetic requirements for maintenance of colorectal cancer$194,724
K22 · FY2014 · CA · contact PI